What is Predictive Biology?
Predictive Biology specializes in the discovery of complex trait etiology through its advanced in vitro genetics platform. By integrating genetics, stem cell biology, organoids, and single-cell technologies, the company elucidates molecular mechanisms and validates novel drug targets. Its core focus areas include neuroscience, preclinical pharmacology, and environmental toxicology. Predictive Biology collaborates with pharmaceutical, biotechnology firms, and academic institutions to advance preclinical pharmacology and stem cell sciences, leveraging proprietary mouse ES cell lines for phenotypic screening and advanced analytical technologies.
How much funding has Predictive Biology raised?
Predictive Biology has raised a total of $58K across 1 funding round:
Debt
$58K
Debt (2021): $58K with participation from PPP
Key Investors in Predictive Biology
PPP
Public-Private Partnership
What's next for Predictive Biology?
With substantial expansion capital, Predictive Biology is poised to scale its operations and further its research into complex traits. The company's strategic focus on integrating cutting-edge technologies like organoids and single-cell analysis suggests an intent to deepen its drug target validation capabilities. Future investments will likely target the expansion of its research pipeline, particularly in neuroscience and preclinical pharmacology, aiming to solidify its position as a key partner for pharmaceutical and biotech innovation.
See full Predictive Biology company page
